

# Top Ten Research Priorities for Pancreatic Cancer Therapy

Klotz et al. (2020)

[https://doi.org/10.1016/S1470-2045\(20\)30179-0](https://doi.org/10.1016/S1470-2045(20)30179-0)

## For which topic were research priorities identified?

pancreatic cancer therapy

## In which location was the research priority setting conducted?

Europe - Germany

## Why was it conducted at all?

Pancreatic cancer is predicted to rise by almost 80% by 2040. Annually, 610 000-915 000 quality-adjusted life-years are lost to pancreatic cancer in Europe, substantially impairing the quality of life (QOL) of patients and caregivers. Treatment options for pancreatic cancer are limited, and only 10-20% of all patients qualify for curative resection with adjuvant chemotherapy. The rate of recurrence after surgery is high, and palliative treatment is associated with toxicities and reduced QOL.

## What was the objective?

to select and prioritize different aspects of research preferences relevant to non-research stakeholders

## What was the outcome?

a ranking list of 10 research questions

## How long did the research prioritization take?

August 2017 - December 2019

## Which methods were used to identify research priorities?

JLA method

## How were the priorities for research identified exactly?

Step 1: setting up PSP: steering group established, stakeholders and partner organizations identified. Step 2: collecting uncertainties: via survey, 519 research questions submitted, further 47 uncertainties added after screening guidelines. Step 3: data processing: combining duplicates, out-of-scope removed, indicative questions formulated, check against literature, resulting in 63 indicative questions. Step 4: interim ranking: with 63 indicative questions. Step 5: final prioritization: workshop

## Which stakeholders took part?

Patients living with pancreatic cancer, their carers, members of patient support groups, and healthcare professionals. Survey: 140 participants (52% patients and carers). Interim ranking: 211 participants (51% patients and carers). Workshop: 25 participants: 7 patient representatives, 13 relatives or carers, and 12 healthcare professionals.

## How were stakeholders recruited?

No information provided.

## Were stakeholders actively involved or did they just participate?

Stakeholders not only participated but were also actively involved in the research prioritization process: They were part of a steering group. The steering group consisted of equal numbers of professional stakeholders and patients with their caregivers. The members decided jointly on all aspects of the PSP.